Reporter brief
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract describes a protocol or planned study, not results—no actual effects on morbidity or mortality are reported
- Sample size, duration, primary outcomes, and effect estimates are not provided, so the magnitude or statistical significance of any effect cannot be assessed
- This appears to be a trial protocol rather than a completed study report
Study design and sample
Rct; Human.
Adults living with obesity
- Design
- Rct
- Sample
- —
- Journal
- Eli Lilly and Company
- Published
- Sep 22, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.